June 13, 1996






Securities & Exchange Commission
Corporate Finance Division
Chief Counsel's Office
450 Fifth Street, N.W.
Washington, DC 20549-1007

RE: Cheung Laboratories, Inc.
      SEC File No. 2-93826-W

Dear Sir or Madam:

Enclosed is an original and four copies of a Form 8K for Cheung
Laboratories, Inc.

Should you have any questions, please give us a call.

Very truly yours,



Augustine Y. Cheung
President




AYC/ls
Enclosures



              SECURITIES AND EXCHANGE COMMISSION

                    Washington, D.C. 20549

                  ___________________________


                            FORM 8-K

                          CURRENT REPORT




                  Pursuant to Section 13 or 15(d) of 
                  the Securities Exchange Act of 1934



Date of Report                                June 13, 1996



                      CHEUNG LABORATORIES, INC.


                               MARYLAND


2-93826-W                   52-1256615
(Commission File Number)    (IRS Employer Identification Number)




10220 Old Columbia Road Suite I Columbia, MD 21046

                                    (410) 290-5390







ITEM 5:  OTHER EVENTS


Cheung Laboratories, Inc. (the "Registrant') has entered into an
exclusive license agreement with Massachusetts Institute of
Technology (MIT) for the commercialization rights to a
proprietary patented Adaptive Phased Array (APA) technology to be
used in conjunction with The Registrant's hyperthermia systems
for the treatment of cancer.   

This innovative proprietary technology was originally developed
by MIT for use in microwave radar systems for the Department of
Defense.  The Registrant believes the use of APA technology with
the Registrant's hyperthermia systems represents a major
breakthrough in the non-invasive  treatment of cancer. A patent
has been granted for the use of APA hyperthermia systems for
non-invasive breast cancer treatment. Patents have also been
granted for use of APA hyperthermia systems for the non-invasive
treatment of deep seated cancer tumors. The APA technology
overcomes the major technological problems of current
hyperthermia systems,  which are  the inability to focus on a
repeatable and reliable basis and the inability to eliminate
undesired hot spots. With the MIT-APA technology, the Registrant
will be in a position to market a complete line of state of the
art, clinically effective and side-effect free hyperthermia
cancer treatment systems for breast cancer, prostate cancer, and
deep-seated tumors in the brain, liver and lungs.  

The Registrant and MIT have been working for over four years in
the antenna design, system development and preclinical evaluation
of the APA technology used with microwave hyperthermia systems.
The initial company effort will be on the  development of a
dedicated breast cancer treatment system that integrates APA with
the Registrant's Microfocus 1000 microwave hyperthermia system. 
The Microfocus 1000 has been approved by the Food and Drug
Administration (FDA) to be used in conjunction with radiation for
cancer treatment.  Adding APA to the Microfocus 1000 will require
clinical studies before marketing and sales in the U.S.A. A
working prototype has been completed with encouraging preclinical
results.  Studies have shown hyperthermia is  effective by
significantly improving the the clinical responses of both
radiation therapy and chemotherapy in cancer treatment. By
itself, hyperthermia reduces the size of tumors. 
     

                          SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf of the undersigned thereunto duly authorized.

                                                                  


                                CHEUNG LABORATORIES, INC.


Date: June 13, 1996        By:______________________________
                                                                  
                           Dr. Augustine Y. Cheung, President